Atigliflozin is a small molecule drug. Atigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment). Atigliflozin has a monoisotopic molecular weight of 382.11 Da.